Current treatments for AMD involving the intravitreal injection of anti-vascular endothelial growth factor (VEGF) are insufficient for complete recovery and RPE cell therapy derived from embryonic stem (ES) cells and induced pluripotent stem cells (iPSC) has been initiated [2,3]. This evidence concerns the gene VEGFA and age-related macular degeneration.